Skip to main content
Journal cover image

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.

Publication ,  Journal Article
Yin, M; Yan, J; Voutsina, A; Tibaldi, C; Christiani, DC; Heist, RS; Rosell, R; Booton, R; Wei, Q
Published in: Lung Cancer
June 2011

BACKGROUND: The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage. METHODS: To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response+partial response vs. stable disease+progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard. RESULTS: We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients. CONCLUSION: There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC.

Duke Scholars

Published In

Lung Cancer

DOI

EISSN

1872-8332

Publication Date

June 2011

Volume

72

Issue

3

Start / End Page

370 / 377

Location

Ireland

Related Subject Headings

  • Xeroderma Pigmentosum Group D Protein
  • Treatment Outcome
  • Survival Analysis
  • Polymorphism, Genetic
  • Platinum Compounds
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Lung Neoplasms
  • Humans
  • Endonucleases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yin, M., Yan, J., Voutsina, A., Tibaldi, C., Christiani, D. C., Heist, R. S., … Wei, Q. (2011). No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer, 72(3), 370–377. https://doi.org/10.1016/j.lungcan.2010.10.011
Yin, Ming, Jingrong Yan, Alexandra Voutsina, Carmelo Tibaldi, David C. Christiani, Rebecca S. Heist, Rafael Rosell, Richard Booton, and Qingyi Wei. “No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.Lung Cancer 72, no. 3 (June 2011): 370–77. https://doi.org/10.1016/j.lungcan.2010.10.011.
Yin, Ming, et al. “No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.Lung Cancer, vol. 72, no. 3, June 2011, pp. 370–77. Pubmed, doi:10.1016/j.lungcan.2010.10.011.
Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, Rosell R, Booton R, Wei Q. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011 Jun;72(3):370–377.
Journal cover image

Published In

Lung Cancer

DOI

EISSN

1872-8332

Publication Date

June 2011

Volume

72

Issue

3

Start / End Page

370 / 377

Location

Ireland

Related Subject Headings

  • Xeroderma Pigmentosum Group D Protein
  • Treatment Outcome
  • Survival Analysis
  • Polymorphism, Genetic
  • Platinum Compounds
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Lung Neoplasms
  • Humans
  • Endonucleases